The clinical genomics of prostate cancer

Abstract

Herein we summarize clinically applicable aspects of the molecular landscape of prostate cancer (PCa), including molecular heterogeneity and subclonality during prostate tumorigenesis and progression. We discuss the major molecular aberrations that define both localized and metastatic prostate cancer and contrast these unique disease states. Finally, we describe the potential utility of using molecular aberrations as prognostic and predictive biomarkers for biochemical and metastatic recurrence, as well as for targeted therapeutics for metastatic castration-resistant prostate cancer.